<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387658</url>
  </required_header>
  <id_info>
    <org_study_id>Dallas VA IRB Protocol #14-076</org_study_id>
    <nct_id>NCT02387658</nct_id>
  </id_info>
  <brief_title>Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient</brief_title>
  <official_title>Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Texas Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Texas Veterans Healthcare System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To perform an observational analysis to determine if mean translesional gradient
           measurements (TLG) are associated with differences in clinical outcomes in patients with
           femoropopliteal arterial disease and claudication.

        2. Hypothesis: Patients stratified by a residual translesional gradient &lt;/= 11 mmHg after
           peripheral revascularization or angiography alone will have better clinical outcomes
           than patients with TLG &gt; 11 mmHg as assessed by six minute walk (6MW), walking
           impairment questionnaire scores (WIQ), ankle brachial index and need for repeat
           procedure at 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of measuring translesional pressure gradients(TLG) in peripheral arterial disease
      lesions below the iliac artery is unclear. In a previous study the investigators demonstrated
      that a pressure wire can be effectively used to measure gradients in the femoropopliteal (FP)
      arterial bed showing good correlation between TLGs recorded with exercise ankle brachial
      index and walking impairment scores. However there is a no evidence that effectively
      modifying the gradient or having a high residual gradient after revascularization or just
      with medical therapy correlates with worse clinical outcomes.

      This is a prospective, single center, observational clinical study to evaluate whether
      measurement of mean residual TLG at the time of angiography and/or immediately after
      endovascular revascularization are associated with clinically important outcomes in patients
      with claudication symptoms.

      Prior to angiography they will be asked to complete an ankle brachial index evaluation,
      baseline six minute walk test and walking impairment questionnaire. Arterial access should be
      obtained in the contralateral common femoral artery to the symptomatic limb if feasible.
      Angiographic images are to be obtained, interpreted and clinical decisions regarding
      endovascular treatment are to be made per treating physician's discretion prior to obtaining
      translesional pressure gradients. In patients whose angiogram does not meet exclusion
      criteria and do not have a chronic total occlusion (CTO) a baseline TLG will be obtained. A
      0.014&quot; pressure wire/catheter to measure pressure will be inserted. After baseline
      calibration in the superficial femoral artery, the wire will be inserted past the narrowest
      lesion into the popliteal vessel. Intra-arterial adenosine 100-200 mcg will be given for
      hyperemia and measurements are to be recorded. If an intervention is planned, repeat
      measurements are to be obtained at the end of the procedure. If no intervention is planned
      this will be the residual or final TLG recorded. If baseline measurement are unable to
      obtained due to a CTO then only a post intervention residual TLG will be obtained and
      included in analysis. The operator will be blinded to the pre and post TLG measurements by
      turning the display monitor away from the procedure table and towards the recorder situated
      in the procedure room when measurements are being obtained.

      Patients will follow up within two weeks post angiography for routine scheduled follow up and
      will obtain repeat ABI, WIQ, and six minute walk if they underwent revascularization.
      Treating physicians and study coordinators collecting these test measurements will be blinded
      to TLG measurements but not to angiography and treatment. Patients will again be evaluated at
      6 months follow up with repeat ABI, WIQ and six minute walk.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in six minute walk distance in meters at 6 months</measure>
    <time_frame>6 months +/- 15 days after enrollment</time_frame>
    <description>Compare change in six minute walk distance at 2 weeks post angiography +/- revascularization to distance walked at 6 months +/- 15 days between patients stratified by a residual mean translesional gradient &gt; 11 mmHg or &lt;/= 11 mmHg. The six minute walk test involves walking in a straight 100m hallway back and forth for as far as possible during a six minute time span.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change Walking Impairment Questionairre (WIQ)Score at 6 months</measure>
    <time_frame>6 months +/- 15 days after enrollment</time_frame>
    <description>Compare change in WIQ scores from within 2 weeks post angiography +/- revascularization to WIQ score at 6 months +/- 15 days between patients stratified by a residual mean translesional gradient &gt; 11 mmHg or &lt;/= 11 mmHg . The walking impairment score used is based on the patient completing short questionnaire about perceived degree of walking impairment at various distances.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle Brachial Index (ABI) at 6 months</measure>
    <time_frame>6months +/- 15 days after enrollment</time_frame>
    <description>Change in ABI between patients stratified by a residual mean translesional gradient &gt; 11 mmHg or &lt;/= 11 mmHg from the index within 2 weeks post TLG measurement to index at 6 months after measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in six minute walk distance from baseline to within 2 weeks post revascularization</measure>
    <time_frame>baseline pre revascularization to two weeks post measurement</time_frame>
    <description>Change in six minute walk from baseline measurement in those patients that undergo revascularization to six minute walk distance checked within 2 weeks after revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WIQ score from baseline to within 2 weeks post revascularization</measure>
    <time_frame>baseline pre revascularization to two weeks post measurement</time_frame>
    <description>Change in WIQ score from baseline measurement in those patients that undergo revascularization to six minute walk distance checked within 2 weeks after revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for repeat revascularization or amputation as assessed by rates of need in repeat revascularization or amputation</measure>
    <time_frame>six months</time_frame>
    <description>compare rates of need in repeat revascularization or amputation between patients stratified by a residual mean translesional gradient &gt; 11 mmHg or &lt;/= 11 mmHg during 6 month period after TLG measurement.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Secondary analysis evaluating correlation between change in 6 minute walk distance at 6 month and residual translesional gradients.</measure>
    <time_frame>6 months</time_frame>
    <description>evaluate for linear correlation between change in six minute walk from baseline to 6 months to mean translesional gradient</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary analysis evaluating correlation in change in WIQ score at 6 month and residual translesional gradients.</measure>
    <time_frame>6 months</time_frame>
    <description>evaluate for linear correlation between change in WIQ from baseline to 6 months to mean translesional gradient</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Claudication</condition>
  <arm_group>
    <arm_group_label>final TLG &lt;/=11 mmHg</arm_group_label>
    <description>includes all patients who have a final mean translesional gradient measurement (TLG) &lt; 11 mmHg regardless if revascularization is done or not.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>final TLG &gt; 11 mmHg</arm_group_label>
    <description>includes all patients who have a final mean translesional gradient measurement (TLG) &gt; 11 mmHg regardless if revascularization is done or not.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>translesional gradient measurement</intervention_name>
    <description>Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.</description>
    <arm_group_label>final TLG &lt;/=11 mmHg</arm_group_label>
    <arm_group_label>final TLG &gt; 11 mmHg</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with claudication symptoms and femoropopliteal disease referred for peripheral
        angiography and possible revascularization.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  At least 18 years old

          -  Unilateral lower limb claudication Rutherford class 2-4

          -  Subjects must be able to complete screening six minute walk, walking impairment
             questionnaire, and baseline ankle brachial index

          -  Estimated survival â‰¥1 year in the judgment of the primary operator

          -  Documented symptomatic femoropopliteal (FP) atherosclerotic disease with at least
             moderate angiographic stenosis in the symptomatic lower extremity

          -  Subjects with multilevel disease can be screened and enrolled after treatment of other
             non FP PAD

        Exclusion Criteria:

          -  Life expectancy less than 12 months or other medical co-morbid condition(s) that could
             limit the subject's ability to participate in the trial, limit the subject's
             compliance with the follow-up requirements, or impact the scientific integrity of the
             trial

          -  Severe Bilateral claudication

          -  Known hypersensitivity or contraindication to contrast dye that, in the opinion of the
             investigator, cannot be adequately pre-medicated

          -  Known hypersensitivity to adenosine or moderate to severe asthma

          -  Pregnancy

          -  Serum Creatinine &gt;2.5

          -  Vascular graft, aneurysm or postsurgical stenosis of the target vessel

          -  Documented untreated severe iliac or below-the knee stenosis with &lt; 2 vessel run-off
             in leg with femoropopliteal stenosis or untreated bilateral symptomatic peripheral
             arterial disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Subhash Banerjee, MD</last_name>
    <email>subhash.banerjee@VA.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Atif Mohammed, MD</last_name>
    <phone>2147428387</phone>
    <phone_ext>76630</phone_ext>
    <email>atif.mohammed@VA.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA North Texas Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subhash Banerjee, MD</last_name>
      <phone>214-742-8387</phone>
      <phone_ext>76630</phone_ext>
      <email>subhash.banerjee@va.gov</email>
    </contact>
    <investigator>
      <last_name>Subhash Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryan Master, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Klein AJ, Pinto DS, Gray BH, Jaff MR, White CJ, Drachman DE; Peripheral Vascular Disease Committee for the Society for Cardiovascular Angiography and Interventions. SCAI expert consensus statement for femoral-popliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014 Oct 1;84(4):529-38. doi: 10.1002/ccd.25504. Epub 2014 Jun 12.</citation>
    <PMID>24753020</PMID>
  </reference>
  <reference>
    <citation>Walker C. What is the role of translesional pressure gradient measurement in peripheral intervention? J Invasive Cardiol. 2011 Sep;23(9):357.</citation>
    <PMID>21891804</PMID>
  </reference>
  <reference>
    <citation>Archie JP Jr. Analysis and comparison of pressure gradients and ratios for predicting iliac stenosis. Ann Vasc Surg. 1994 May;8(3):271-80.</citation>
    <PMID>8043361</PMID>
  </reference>
  <reference>
    <citation>Banerjee S, Badhey N, Lichtenwalter C, Varghese C, Brilakis ES. Relationship of walking impairment and ankle-brachial index assessments with peripheral arterial translesional pressure gradients. J Invasive Cardiol. 2011 Sep;23(9):352-6.</citation>
    <PMID>21891803</PMID>
  </reference>
  <reference>
    <citation>Garcia LA, Carrozza JP Jr. Physiologic evaluation of translesion pressure gradients in peripheral arteries: comparison of pressure wire and catheter-derived measurements. J Interv Cardiol. 2007 Feb;20(1):63-5.</citation>
    <PMID>17300406</PMID>
  </reference>
  <reference>
    <citation>De Bruyne B, Manoharan G, Pijls NH, Verhamme K, Madaric J, Bartunek J, Vanderheyden M, Heyndrickx GR. Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol. 2006 Nov 7;48(9):1851-5. Epub 2006 Oct 17.</citation>
    <PMID>17084261</PMID>
  </reference>
  <reference>
    <citation>Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR 3rd, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA; Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003 Apr 28;163(8):884-92. Review.</citation>
    <PMID>12719196</PMID>
  </reference>
  <reference>
    <citation>Tetteroo E, van Engelen AD, Spithoven JH, Tielbeek AV, van der Graaf Y, Mali WP. Stent placement after iliac angioplasty: comparison of hemodynamic and angiographic criteria. Dutch Iliac Stent Trial Study Group. Radiology. 1996 Oct;201(1):155-9.</citation>
    <PMID>8816537</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Texas Veterans Healthcare System</investigator_affiliation>
    <investigator_full_name>Subhash Banerjee</investigator_full_name>
    <investigator_title>Chair of Cardiology North Texas VA Medical Center</investigator_title>
  </responsible_party>
  <keyword>peripheral arterial disease</keyword>
  <keyword>claudication</keyword>
  <keyword>translesional pressure gradient</keyword>
  <keyword>pressure wire</keyword>
  <keyword>six minute walk</keyword>
  <keyword>superficial femoral artery</keyword>
  <keyword>pressure gradient</keyword>
  <keyword>endovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

